Target intelligence / Profile preview

Bcl-2 protein family (Bcl-2)

Target
Bcl-2
Molecular classification
Apoptosis regulator protein family, Mitochondrial outer membrane protein family, Antiapoptotic protein (for Bcl-2, Bcl-XL, Mcl-1 subfamily), Proapoptotic effector protein (for Bax, Bak subfamily), Proapoptotic BH3-only protein (for BAD, BID, PUMA, NOXA subfamily)
01

Overview

The **Bcl-2 protein family** is a group of structurally related proteins central to the regulation of apoptosis (programmed cell death), primarily through control of mitochondrial outer membrane permeabilization (MOMP). This family is comprised of both antiapoptotic members (such as Bcl-2, Bcl-XL, and Mcl-1), which block apoptosis and promote cell survival, and proapoptotic members—including effector proteins (Bax, Bak) and BH3-only proteins (BAD, BID, PUMA, NOXA)—which promote cell death by enabling mitochondrial membrane permeabilization and the release of apoptogenic factors such as cytochrome c. The intricate balance and interaction between these proteins determines the commitment to cell survival or death. Dysregulation of Bcl-2 family proteins is a hallmark of several diseases, especially various cancers, making them key therapeutic targets. Drugs called BH3 mimetics, such as venetoclax, have been developed to inhibit antiapoptotic members, thereby inducing apoptosis in cancer cells.

Other names
Bcl-2 familyBCL2 familyB-cell lymphoma 2 family
02

Mechanism of action

Inhibition of antiapoptotic Bcl-2 proteins (restores apoptosis in cancer cells); Disruption of Bcl-2 or Bcl-XL binding to proapoptotic members (BH3 mimetics)

03

Biological functions

Regulation of apoptosisMitochondrial membrane permeabilization controlCell deathRegulation of mitochondrial dynamics (fusion/fission)Signal transduction (including calcium signaling and metabolic regulation)
04

Disease associations

Cancer (especially lymphoma, leukemia, solid tumors)Neurodegenerative diseaseCardiovascular diseaseImmune dysregulation/autoimmunity
05

Safety considerations

On-target toxicity (e.g., thrombocytopenia, neutropenia)Tumor lysis syndrome (rapid apoptosis in cancers)Resistance mechanisms (e.g., upregulation of other antiapoptotic proteins like MCL-1)
06

Interacting drugs

Venetoclax (ABT-199)

5 more in the full profile.

07

Biomarkers

BCL2 expression by immunohistochemistry (IHC)BCL2 mRNA expressionMolecular signatures of Bcl-2 family dysregulation in tumors

Beyond the preview

Go deeper on Bcl-2 protein family (Bcl-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bcl-2 protein family (Bcl-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call